iiinova — where your digital self keeps evolving

ACIR @acir-org.bsky.social · 29/09/2026

Asano, Veatch, and Sung et al. identified TCRMCC1, a high-avidity HLA-A*02:01-restricted TCR targeting Merkel cell polyomavirus large-T antigen and treated seven patients who had ICI-refractory metastatic MCC using autologous TCRMCC1-transduced [...] @fredhutch.org bit.ly/46BEhGz

000

ACIR @acir-org.bsky.social · 28/09/2026

Using scRNA sequencing, Ng et al. compared LN biopsy samples (non-affected vs. tumor-affected) from SCLC patients to study the antitumor role of MHC-I-independent pathways. bit.ly/4rAAbrS @wehi-research.bsky.social

000

ACIR @acir-org.bsky.social · 25/09/2026

Smith, Dao, and Gavil et al. showed that activation of unexhausted non-tumor-specific memory T cells in the TIME induced tumor clearance in the absence of NK cell- or TCRαβ-dependent tumor cell recognition, although the latter[...] bit.ly/4AsZ38H @oliviacs.bsky.social @cfi-umn.bsky.social

000

ACIR @acir-org.bsky.social · 25/09/2026

Qing and Ghorani et al. explored mechanisms of secondary resistance (2°R) to therapy (Treg depletion via anti-CD25 mAb + GM-CSF-expressing tumor cell vaccine) in B16 tumor- bearing mice. @aacrjournals.bsky.social bit.ly/4h9JjA1

001

ACIR @acir-org.bsky.social · 24/09/2026

Haratani et al. found that most neoantigens arising from truncal mutations in TP53 were not presented, either because they arose from processing-resistant regions of p53 or because the required HLA allele was absent. bit.ly/4ArRQ91 @danafarbernews.bsky.social

000

ACIR @acir-org.bsky.social · 24/09/2026

Falcomatà et al. used perturb-map spatial functional genomics to identify tumor-derived extracellular factors that promote PDAC immune evasion. bit.ly/4yaTJ8r @chiarafalcomata.bsky.social @brownlab1.bsky.social

000

ACIR @acir-org.bsky.social · 23/09/2026

PLA2G2D, produced by a unique subset of lymph node macrophages, suppresses T cells and could be targeted for immunotherapy acir.org/weekly-dige...

000

ACIR @acir-org.bsky.social · 22/09/2026

Ibrahim et al. profiled sotorasib-induced changes in syngeneic KRASG12C/Trp53−/− lung and colon carcinoma models with and without anti-PD-1. bit.ly/4h4qUTW @aacrjournals.bsky.social

001

ACIR @acir-org.bsky.social · 21/09/2026

Tian et al. fused second-generation CAR-macrophages with neutrophils, generating syncytial (S)-CAR-M with enhanced chemokine-driven solid tumor infiltration and cytotoxicity. bit.ly/4xZBIda

000

ACIR @acir-org.bsky.social · 18/09/2026

Golubovskaya et al. showed that intratumoral delivery of an anti-human EpCAM-CD3 BiTE mRNA-LNP stops growth of only directly injected EpCAM+ human tumor xenografts in immuno-incompetent mice (with i.v. human T cells). bit.ly/3Typnha

010

ACIR @acir-org.bsky.social · 17/09/2026

Xiang et al. developed a DC-directed dual pH-gated hybrid nanoparticle (HNP) that sequentially releases αCD47 peptides in the acidic TIME to enhance antigen acquisition and subsequently cGAMP under endosomal acidification to activate intracellular STING. bit.ly/3SMR1a3

000

ACIR @acir-org.bsky.social · 17/09/2026

Nishida et al. sought to prevent carcinogen (NMU)-induced mammary tumorigenesis in outbred Sprague-Dawley rats by targeting LALBA, a protein specifically expressed in luminal progenitor (LP) cells – the proposed cell-of-origin for breast cancer. bit.ly/3UZwj7q

000

ACIR @acir-org.bsky.social · 16/09/2026

Fine-tuning IL-2 delivery for cancer immunotherapy acir.org/weekly-dige...

011

ACIR @acir-org.bsky.social · 15/09/2026

Lin et al. developed a longitudinal scRNAseq atlas of 441 ICI-treated tumors from 241 patients across 10 cancer types, and identified 4 conserved TIME states. bit.ly/3SYlx0t

000

ACIR @acir-org.bsky.social · 14/09/2026

Groeneveldt et al. investigated mechanisms driving early-stage immune-related adverse events (irAEs) in patients with metastatic melanoma treated with combination ICB (anti-PD-1 and anti-CTLA-4). bit.ly/4A4rx8O @aacrjournals.bsky.social

011

ACIR @acir-org.bsky.social · 11/09/2026

Swatler, Puccio, et al. used scRNsSeq and flow cytometry to define Treg subsets and analyze heterogeneity and TCR overlap across tissues from 9 tumor types. bit.ly/4yo9RTL

000

ACIR @acir-org.bsky.social · 11/09/2026

Liu et al. developed a genome-wide in vivo CRISPR screening platform using a T cell-attracting anti-CD3 scFv-expressing A375 tumor model and primary human T cells to identify in vivo regulators of intratumoral T cell abundance and effector function. bit.ly/4xhHzth

010

ACIR @acir-org.bsky.social · 10/09/2026

Arisato et al. found that the LLC-2B2 subclone of LLC was universally rejected in ICB-treated WT mice and was also rejected in 36% of ICB-treated Batf3-/- mice. In Batf3-/- mice, rejection was dependent on CD8+ T cells primed by alternative XCR1- APCs, which [...] bit.ly/3SF8l0B

000

ACIR @acir-org.bsky.social · 10/09/2026

Ex vivo-differentiated cDC1s offer superior tumor protection compared to monocyte-derived DCs used in DC vaccine trials. bit.ly/4xKS6y1

000

ACIR @acir-org.bsky.social · 09/09/2026

Enfortumab vedotin (Padcev) is approved for use in a number of clinical indications, and Olson and Liu et al. recently returned to the preclinical setting to untangle its mechanism acir.org/weekly-dige...

000

ACIR @acir-org.bsky.social · 08/09/2026

Sun et al. performed multi-omics analysis across nine stages of mouse HCC lung metastatic colonization, with supporting human data, to map the co-evolution of disseminated tumor cells (DTCs) and host immune niches. bit.ly/4i3Erxh

000

ACIR @acir-org.bsky.social · 07/09/2026

Ottensmeier and Delord et al. report a randomized phase I trial of adjuvant TG4050, an individualized MVA-vectored neoantigen vaccine encoding up to 30 predicted neoantigens, in high-risk resected HNSCC. bit.ly/4gF6TmM

000

ACIR @acir-org.bsky.social · 04/09/2026

Zhu and Yu et al. developed and characterized a scalable, feeder-free, high-yield platform that generated allogeneic NY-ESO-1-specific cytotoxic T (AlloESO-T) cells from cord blood-derived hematopoietic stem and progenitor cells. bit.ly/4qNx1QS

000

ACIR @acir-org.bsky.social · 04/09/2026

Zhu, Dann, et al. developed a transcriptome-wide and transcription factor genome-wide CRISPRi knockdown perturb-seq platform for human CD4+ T cells to comprehensively identify functional gene networks. bit.ly/46FO26g

000

ACIR @acir-org.bsky.social · 03/09/2026

Takacsi-Nagy et al. generated a library of synthetic T cell Transcription Factors through combinatorial assembly of AP-1 family TF subdomains. Expressed in CAR-T cells, certain sTFs improved CAR-T persistence/proliferation over natural TFs in a chronic stimulation assay. bit.ly/4qR03z5

000

ACIR @acir-org.bsky.social · 03/09/2026

Xu et al. identified optimal and reproducible culture and cytokine conditions to create universal, human iPSC-derived DCs lacking HLA (B2m/CTIIA KO) and with a CCR7+ migratory DC phenotype. bit.ly/4iIlGQ4

000

ACIR @acir-org.bsky.social · 02/09/2026

Role of AIRE in tumors acir.org/weekly-dige...

010

ACIR @acir-org.bsky.social · 25/08/2026

King-Peoples et al. assessed the Tn-glycosylated IIICS domain of fibronectin (Tn-FN) as an ECM-derived CAR target, and generated FDC6-BBζ CAR T cells using the FDC6 mAb. bit.ly/4x7ZXWd @aacrjournals.bsky.social

011

ACIR @acir-org.bsky.social · 24/08/2026

Lu et al. profiled the cellular changes after KRAS(G12C) and MEK inhibition, and demonstrated that these treatments drove distinct neoplastic cell fates and immune responses in a CT26 KRASG12C tumor model. @aacrjournals.bsky.social @amgen.bsky.social bit.ly/4bSy8ZC

021

ACIR @acir-org.bsky.social · 21/08/2026

In a phase 1 trial, Li and Zhou et al. evaluated the EGFR-targeting, topoisomerase I inhibitor JS-1-carrying ADC SYS6010 in 236 patients with previously treated, advanced NSCLC (diverse subtypes and EGFR status). bit.ly/4giJiYH

001

ACIR @acir-org.bsky.social · 21/08/2026

Avraham and Barth et al. focused on optimizing the therapeutic potential of agonistic anti-GITR mAbs. Fc-engineered versions of human anti-GITR mAbs were evaluated in humanized FcγR mice. @yahelav.bsky.social @weizmann.ac.il @dahanlab.bsky.social bit.ly/4zsjS3N

000

ACIR @acir-org.bsky.social · 20/08/2026

In a phase 1 trial, Zhang, Chi, and Feng et al. treated 15 patients with B7-H3+ recurrent GBM with local delivery (intra-cerebroventricular or tumor cavity) of autologous B7-H3 CAR T cells. bit.ly/469UeTW

000

ACIR @acir-org.bsky.social · 20/08/2026

Li et al. performed a multiyear study, prospectively analyzing peripheral immune cells and plasma cytokines from 124 patients with advanced pan-solid tumors treated with anti-PD-L1 or anti-PD-1. @aacrjournals.bsky.social bit.ly/4xa0kzK

021

ACIR @acir-org.bsky.social · 19/08/2026

New research shows that melanocytes utilize PD-L1 to protect themselves from immune-mediated clearance of UV-mutated cells acir.org/weekly-dige...

010

ACIR @acir-org.bsky.social · 18/08/2026

Kumar et al. characterized the transcriptome and proteome of the DC compartment in both pediatric and adult ALL, and demonstrated that DC maturation into functional lineages was disrupted. [...] @cityofhope.bsky.social bit.ly/4wsVP23

000

ACIR @acir-org.bsky.social · 17/08/2026

Kang and Han et al. developed PROTEXI, a vaccine platform comprising autologous DCs loaded with both tumor-specific CD8+ T and SARS-CoV-2 Spike protein CD4+ TH cell epitopes. In mouse tumor models, PROTEXI required both [...] bit.ly/4i9RgpA

000

ACIR @acir-org.bsky.social · 14/08/2026

Naara, Kochat, and Rao et al. compared the TIMEs of immunocompetent non-melanoma skin cancer (NMSC) patients and systemically immunosuppressed (IS) patients (organ transplant recipients or hematological cancer) who had reduced survival. bit.ly/4cCv2ZQ @mdanderson.bsky.social

000

ACIR @acir-org.bsky.social · 14/08/2026

To overcome PDAC resistance to Kras* targeting using MRTX1133 or daraxonrasib, which enhances infiltration T cells, including various CD8+ T cell, CD4+ conventional T cell, and Treg phenotypes, Mahadevan et al. found [...] @mdanderson.bsky.social bit.ly/3SxYFVr

000

ACIR @acir-org.bsky.social · 13/08/2026

In a phase 1 trial, Haldar, Huff, et al. treated 20 volunteers with high-risk of PDAC development (based on family history or genetics, plus radiographic indication of a precursor lesion/cyst) with [...] @aacrjournals.bsky.social @hopkinsmedicine.bsky.social bit.ly/4qeqDlE

011

ACIR @acir-org.bsky.social · 13/08/2026

Vleeshouwers et al. showed that the time of antigen encounter determines the differentiation of antigen-specific CD8+ T cells and antiviral immunity. @unileiden.bsky.social bit.ly/4bNpvzj

000

ACIR @acir-org.bsky.social · 11/08/2026

Afeyan, Nagler, and Tu et al. investigated how tertiary lymphoid structures (TLSs) impact phenotypic properties of tumor-specific T cells in treatment-naive renal carcinoma (RCC). bit.ly/4bvUmAl @broadinstitute.org

020

ACIR @acir-org.bsky.social · 10/08/2026

Evaluating patient NSCLC tumors treated with neoadjuvant anti-PD-1 and enriched for tertiary lymphoid structures, Meyerhoff, Chen, and O’brien et al. used transcriptomic data to identify B cell populations, including CD138+ plasma cells [...] @dukemedschool.bsky.social bit.ly/459K6Kw

000

ACIR @acir-org.bsky.social · 09/08/2026

Nagler, Sud, and Ghannam et al. developed a droplet-based single-nucleus spatial transcriptomics platform, Slide-GoTags, that integrates genotyping, TCR sequencing, and snRNAseq from the same frozen section to map [...] @amitsud.bsky.social @harvardmed.bsky.social bit.ly/4fPg8jO

011

ACIR @acir-org.bsky.social · 07/08/2026

Inspired by clinical data that the neuropeptide vasoactive intestinal peptide (VIP), acting through its receptor (VIPR), was correlated with poor response in patients undergoing CAR therapy, Lin et al. used [...] bit.ly/4wMwnWa @winshipcancer.emory.edu @sarwishrafiq.bsky.social

010

ACIR @acir-org.bsky.social · 07/08/2026

Rouanne et al. engineered probiotic E.coli (EcN) using a synchronized lysis integrated circuit to release human CXCL13 at critical population densities, without impeding normal bacterial growth. bit.ly/4q0QeOR @columbiauniversity.bsky.social

110

ACIR @acir-org.bsky.social · 06/08/2026

Karapetyan et al. profiled TIL infusion products and matched TIMEs from patients with metastatic melanoma treated on TIL-based trials with or without ICB or BRAFi, and found that responders had infusion products enriched for stem-like memory [...] @moffittnews.bsky.social bit.ly/4xlR1fs

000

ACIR @acir-org.bsky.social · 06/08/2026

Role of CD4s in ICB acir.org/weekly-dige...

010

ACIR @acir-org.bsky.social · 04/08/2026

Banerjee et al. showed that Tim3 expression on tumor-infiltrating Tregs was required for their survival and suppressive function via Akt-FOXO1 signaling. Treg-specific Tim3 deletion in an MC38 model reduced tumor-infiltrating Tregs and CD25 expression, impaired Treg [...] bit.ly/4wxVfRo

021